Patients receiving these drugs require careful monitoring to manage side effects and assess the effectiveness of treatment. Blood tests are routinely performed to check for myelosuppression and organ function. Cardiac monitoring is often necessary for patients receiving anthracyclines like doxorubicin, given the risk of long-term heart damage.
